<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03420040</url>
  </required_header>
  <id_info>
    <org_study_id>KY20172077-1</org_study_id>
    <nct_id>NCT03420040</nct_id>
  </id_info>
  <brief_title>A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use</brief_title>
  <official_title>A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study of the use of glargine insulin in 2 subjects with type two diabetes in China&#xD;
      was carried out. The two kinds of injection methods were evaluated as subcutaneous injection&#xD;
      of insulin glargine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fasting blood glucose between baseline to week 4</measure>
    <time_frame>baseline and week 4</time_frame>
    <description>fasting blood glucose are measured at baseline and week 4</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>QS-M Needle Free Injector group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To observe the use of insulin in glycemia under good blood glucose control in the QS-M Needle Free Injector group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glargine pen group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To observe the amount of insulin used by the Glargine pen group under good blood glucose control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QS-M Needle Free Injector</intervention_name>
    <description>The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection</description>
    <arm_group_label>QS-M Needle Free Injector group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glargine pen</intervention_name>
    <description>The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection</description>
    <arm_group_label>Glargine pen group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male or female aged 18-70 years of age, women of childbearing age need to take&#xD;
             adequate contraceptive measures to minimize the risk of pregnancy;&#xD;
&#xD;
          2. the standard of diagnosis of type 2 diabetes and the course of the disease is more&#xD;
             than half a year;&#xD;
&#xD;
          3. 18 Kg/m2 = BMI = 30Kg/m2;&#xD;
&#xD;
          4. received daily injections of insulin glargine and also take one to three kinds of oral&#xD;
             medicine (not including secretagogues) patients, daily insulin glargine total dose&#xD;
             more than 12IU but &lt;50IU, the use of insulin glargine than in January;&#xD;
&#xD;
          5. the blood glucose in the fasting vein was in 5.0-9.0mmol/L;&#xD;
&#xD;
          6. the letter of informed consent has been read and signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. there is conflict of interest with this research.&#xD;
&#xD;
          2. blood glucose control is not good enough to participate in this study, such as&#xD;
             repeated hypoglycemia, diabetic ketoacidosis or hyperosmolar coma.&#xD;
&#xD;
          3. serious diabetic complications such as diabetic foot, diabetic nephropathy and so on;&#xD;
&#xD;
          4. severe cardiovascular events occurred in the last 6 months.&#xD;
&#xD;
          5. the application of hormone or immunosuppressant, or low immunity defect;&#xD;
&#xD;
          6. the use of non steroidal anti-inflammatory drugs;&#xD;
&#xD;
          7. the use of sulfonylureas and insulin secreting agents;&#xD;
&#xD;
          8. a person with a history of cancer;&#xD;
&#xD;
          9. a history of unstable or rapid progressive renal disease;&#xD;
&#xD;
         10. an unstable history of major mental illness;&#xD;
&#xD;
         11. the history of hemoglobin (such as sickle red cell anemia, thalassemia, iron&#xD;
             granulocytic anemia);&#xD;
&#xD;
         12. women who are pregnant or are breastfeeding;&#xD;
&#xD;
         13. in the near future there is a clear infection, such as urinary tract infection and&#xD;
             pneumonia;&#xD;
&#xD;
         14. recent important visceral hemorrhage, such as gastric hemorrhage and cerebral&#xD;
             hemorrhage, etc.&#xD;
&#xD;
         15. skin diseases such as exfoliative dermatitis, pustular sore and infection of pyogenic&#xD;
             bacteria;&#xD;
&#xD;
         16. the history of acute pancreatitis or pancreatectomy;&#xD;
&#xD;
         17. the researchers believe that it may lead to any situation in which the subject is&#xD;
             unable to complete the study or may cause significant risk to the subject.&#xD;
&#xD;
         18. the results of the laboratory examination are as follows: A. obvious abnormal liver&#xD;
             function or in the active phase of the disease (AST&gt; 3 times the upper limit of normal&#xD;
             ALT&gt; or 3 times the upper limit of normal); The creatinine clearance rate of B. was&#xD;
             &lt;60ml/min; C. anaemia caused by any cause of the disease; The results of pregnancy&#xD;
             test in women of childbearing age of D. were positive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiuhe Ph.D Ji, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology, Xijing Hospital, Fourth Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hospital, Fourth Military Medical university</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glargine Insulin</keyword>
  <keyword>QS-M Needle Free Injector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 3, 2020</submitted>
    <returned>September 24, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

